Related Experiment Video
Updated: Jan 14, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using
Pierre Heudel1, Gema Hernandez2, Olivier Denquin2
1Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon, 69008, France, 33478782952.
Background:
Survivors of metastatic lung cancer (MLC) face a heightened risk of developing second primary cancers (SPCs), which significantly impact long-term outcomes. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their potential role in reducing SPC risk remains underexplored. This study investigates the association between ICI treatment and the incidence of SPCs in a large, real-world cohort of patients with MLC.
Objective:
This study aims to evaluate whether treatment with ICIs is associated with a reduced risk of developing SPCs in patients with metastatic or locally advanced lung cancer, using real-world data from the TriNetX global health research network.
Methods:
We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, which aggregates deidentified electronic health records from more than 135 million patients. Adults diagnosed with MLC between February 2004 and February 2024 were included. Patients were divided into 2 cohorts based on ICI exposure. Propensity score matching was applied to balance baseline characteristics. Kaplan-Meier survival analysis and Cox proportional hazards models were used to assess the incidence of SPCs and the composite outcome of SPC or death.
Results:
Among 2844 eligible patients, 685 received ICIs and 2157 did not. After propensity score matching, both cohorts included 685 patients. The 5-year incidence of SPCs was lower in the ICI group (1.5%) compared to the non-ICI group (4.2%), with a hazard ratio of 0.49 (95% CI 0.24-1.01), suggesting a potential protective effect. Furthermore, ICI treatment was significantly associated with a reduced risk of the composite outcome of SPC or death (hazard ratio 0.74, 95% CI 0.62-0.89). Median follow-up was 20.2 (IQR 60-not reached) months for the ICI group and 68.4 (IQR 36-not reached) months for the non-ICI group.
Conclusions:
In this large real-world cohort, ICI treatment was associated with a lower risk of developing SPCs and improved overall outcomes in patients with MLC. These findings support the hypothesis that ICIs may offer a preventive benefit beyond their primary oncologic indications. While the retrospective nature and data limitations warrant cautious interpretation, this study underscores the value of real-world evidence in identifying novel therapeutic benefits and guiding future prospective research.
Insights
Immune checkpoint inhibitors (ICIs) may reduce the risk of second primary cancers (SPCs) in metastatic lung cancer (MLC) survivors. This real-world study found lower SPC incidence and improved outcomes with ICI use, suggesting a potential preventive benefit.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Epidemiology
Background:
- Metastatic lung cancer (MLC) survivors have an increased risk of second primary cancers (SPCs), impacting long-term prognosis.
- Immune checkpoint inhibitors (ICIs) have transformed cancer care, but their role in SPC prevention is not well understood.
Purpose of the Study:
- To investigate the association between ICI treatment and the incidence of SPCs in a large, real-world cohort of MLC patients.
- To evaluate if ICIs reduce the risk of SPCs in patients with metastatic or locally advanced lung cancer using real-world data.
Main Methods:
- Retrospective cohort study utilizing the TriNetX Global Collaborative Network (over 135 million deidentified EHRs).
- Included adults diagnosed with MLC between February 2004 and February 2024.
- Applied propensity score matching and survival analyses (Kaplan-Meier, Cox models) to compare ICI-exposed and non-exposed cohorts regarding SPC incidence and overall outcomes.
Main Results:
- After propensity score matching, 685 patients were in the ICI group and 685 in the non-ICI group.
- The 5-year SPC incidence was lower in the ICI group (1.5%) versus the non-ICI group (4.2%), hazard ratio (HR) 0.49 (95% CI 0.24-1.01).
- ICI treatment was significantly associated with a reduced risk of SPC or death (HR 0.74, 95% CI 0.62-0.89).
Conclusions:
- ICI treatment in MLC patients is linked to a reduced risk of SPCs and improved overall survival in a real-world setting.
- Findings suggest ICIs may provide a preventive benefit beyond their direct anti-cancer effects.
- Real-world evidence highlights ICIs' potential for novel therapeutic benefits and guides future research directions.
